NextCure (NASDAQ:NXTC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of NextCure (NASDAQ:NXTC) to a hold rating in a research note issued to investors on Saturday morning.

A number of other equities research analysts have also weighed in on NXTC. LADENBURG THALM/SH SH upgraded NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a research report on Friday, October 31st. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.00.

NextCure Price Performance

NextCure stock opened at $11.47 on Friday. The stock has a market cap of $30.74 million, a price-to-earnings ratio of -0.48 and a beta of 1.54. The firm has a 50-day moving average of $10.37 and a two-hundred day moving average of $7.17. NextCure has a 1 year low of $2.69 and a 1 year high of $15.74.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($3.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.06) by $0.84. Research analysts expect that NextCure will post -1.87 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in NextCure stock. Cable Car Capital LP lifted its holdings in NextCure, Inc. (NASDAQ:NXTC) by 13.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 758,141 shares of the company’s stock after purchasing an additional 88,040 shares during the period. Cable Car Capital LP owned about 28.29% of NextCure worth $349,000 as of its most recent filing with the Securities & Exchange Commission. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.